Get the Stockscreener App
5.62
3.60%
-0.21
Pre-market:
5.74
0.12
+2.14%
Aquestive Therapeutics Inc stock is traded at $5.62, with a volume of 2.73M.
It is down -3.60% in the last 24 hours and down -24.97% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$5.83
Open:
$5.84
24h Volume:
2.73M
Relative Volume:
0.88
Market Cap:
$560.45M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-15.44
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
+6.04%
1M Performance:
-24.97%
6M Performance:
+135.15%
1Y Performance:
+18.69%
1-Day Range:
$5.54
$6.168
1-Week Range:
$5.21
$6.168
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
5.62 | 711.28M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Why Aquestive Therapeutics Inc. stock is favored by top institutionsTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
How to monitor Aquestive Therapeutics Inc. with trend dashboardsEarnings Risk Report & High Return Stock Watch Alerts - newser.com
Can Aquestive Therapeutics Inc. stock sustain revenue growthPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Why Aquestive Therapeutics Inc. stock is trending among retail tradersMarket Performance Summary & Proven Capital Preservation Tips - newser.com
Why Aquestive Therapeutics Inc. stock could outperform in 2025July 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Aquestive Therapeutics Inc. stock momentum explainedMarket Rally & High Accuracy Trade Signal Alerts - newser.com
Risk vs reward if holding onto Aquestive Therapeutics Inc.Swing Trade & Real-Time Market Sentiment Reports - newser.com
Officer Kraus Files To Sell 53,100 Of Aquestive Therapeutics Inc [AQST] - TradingView
Aquestive Therapeutics (AQST) Price Target Increased by 14.80% to 10.51 - Nasdaq
Will Aquestive Therapeutics Inc. bounce back from current supportLayoff News & AI Based Buy and Sell Signals - newser.com
Can trapped investors hope for a rebound in Aquestive Therapeutics Inc.Analyst Upgrade & Daily Oversold Stock Bounce Ideas - newser.com
Predicting Aquestive Therapeutics Inc. trend using moving averagesJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges - MSN
Aquestive Therapeutics (NASDAQ:AQST) Updates Amid Dow Jones Industrial Average - Kalkine Media
Why Aquestive Therapeutics Inc. stock is favored by pension fundsPortfolio Growth Summary & Real-Time Market Trend Scan - newser.com
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors - simplywall.st
Using R and stats models for Aquestive Therapeutics Inc. forecastingInsider Buying & AI Based Buy/Sell Signal Reports - newser.com
Can technical indicators confirm Aquestive Therapeutics Inc.’s reversalTrade Risk Summary & Weekly High Potential Alerts - newser.com
Will Aquestive Therapeutics Inc. stock attract more institutional investorsWeekly Gains Report & Growth Focused Entry Reports - Fundação Cultural do Pará
Will Aquestive Therapeutics Inc. stock outperform tech sector in 20252025 Trading Volume Trends & Weekly Hot Stock Watchlists - Fundação Cultural do Pará
Aquestive Therapeutics Q3 2025 Earnings Preview - MSN
Will Aquestive Therapeutics Inc. stock gain from strong economy2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec” - Insider Monkey
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.17%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):